Publicação
Comparison of three assays for total and free PSA using hybritech and WHO calibrations
| dc.contributor.author | Garrido, Manuel M. | |
| dc.contributor.author | Marta, Jose C. | |
| dc.contributor.author | Ribeiro, Ruy M. | |
| dc.contributor.author | Pinheiro, Luis C. | |
| dc.contributor.author | Holdenrieder, Stefan | |
| dc.contributor.author | Guimaraes, Joao T. | |
| dc.contributor.institution | NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) | |
| dc.contributor.pbl | International Institute of Anticancer Research | |
| dc.date.accessioned | 2023-01-12T22:17:21Z | |
| dc.date.available | 2023-01-12T22:17:21Z | |
| dc.date.issued | 2021-12 | |
| dc.description | Publisher Copyright: © 2021 International Institute of Anticancer Research. All rights reserved. | |
| dc.description.abstract | Background/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cobas® and the Abbott Architect® methods. Results: Roche tPSA values were ≈ 1% higher than Beckman, while Abbott values were ~5% lower. Roche had the highest diagnostic sensitivity (92%) compared to Beckman Coulter (87%) and Abbott (85%). Roche fPSA was ≈3% lower and Abbott ≈17% higher than that of Beckman. For the percentage of fPSA, Roche had the highest sensitivity (98%). Conclusion: Roche cobas® and Beckman Coulter Access® Hybritech® tPSA were almost interchangeable. While the agreement was acceptable for tPSA, this did not happen with fPSA and greater efforts for harmonization are required. | en |
| dc.description.version | publishersversion | |
| dc.description.version | published | |
| dc.format.extent | 9 | |
| dc.format.extent | 1508550 | |
| dc.identifier.doi | 10.21873/invivo.12643 | |
| dc.identifier.issn | 0258-851X | |
| dc.identifier.other | PURE: 35103969 | |
| dc.identifier.other | PURE UUID: befd14c0-c1a4-4b7d-82f1-ea96f1d1b1f4 | |
| dc.identifier.other | Scopus: 85119267799 | |
| dc.identifier.other | WOS: 000711693300028 | |
| dc.identifier.uri | http://hdl.handle.net/10362/147444 | |
| dc.identifier.url | https://www.scopus.com/pages/publications/85119267799 | |
| dc.language.iso | eng | |
| dc.peerreviewed | yes | |
| dc.subject | Free PSA | |
| dc.subject | Hybritech calibration | |
| dc.subject | Method comparison | |
| dc.subject | Prostate cancer | |
| dc.subject | Total PSA | |
| dc.subject | WHO calibration | |
| dc.subject | General Biochemistry,Genetics and Molecular Biology | |
| dc.subject | Pharmacology | |
| dc.subject | SDG 3 - Good Health and Well-being | |
| dc.title | Comparison of three assays for total and free PSA using hybritech and WHO calibrations | en |
| dc.type | journal article | |
| degois.publication.firstPage | 3431 | |
| degois.publication.issue | 6 | |
| degois.publication.lastPage | 3439 | |
| degois.publication.title | In Vivo | |
| degois.publication.volume | 35 | |
| dspace.entity.type | Publication | |
| rcaap.rights | openAccess |
Ficheiros
Principais
1 - 1 de 1